Oral Contraceptive Interaction Study for GW273225
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00483535|
Recruitment Status : Terminated
First Posted : June 7, 2007
Last Update Posted : August 8, 2017
GW273225 is in development for epilepsy and bipolar disorder and can affect women of child bearing potential. A clear understanding of the potential interaction between oral contraceptives and GW273225 is therefore important for clinical investigation of GW273225 in a large number of patients. This study will investigate whether there is any effect of GW273225 upon the components of combined oral contraceptive, and also whether taking oral contraceptives affects the pharmacokinetics (PK) of GW273225.
26 healthy female subjects, aged 18-45 years will take an oral contraceptive (150ug levonorgestrel and 30ug ethinylestrdiol; The study will include a screening period, two cycles on oral contraceptive with GW273225 at 25 mg once per day administered from the start of the second COC cycle for 47 days. There will be a follow-up visit 14-21 days later.
|Condition or disease||Intervention/treatment||Phase|
|Bipolar Disorder||Drug: GW273225 Drug: COC||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open, Repeat Dose Study to Investigate the Effect of Co-administration of the Combined Oral Contraceptive Pill (COC) and GW273225 on the Pharmacokinetics of the COC and to Investigate the Effects of the COC on the Pharmacokinetics of GW273225 in Healthy Female Subjects|
|Actual Study Start Date :||March 7, 2007|
|Primary Completion Date :||November 16, 2007|
|Study Completion Date :||November 16, 2007|
Experimental: Sequence ABC
All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
GW273225 will be available as 25 milligram tablets.Drug: COC
COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
- 0-24hrs PK of oral contraceptive components [ Time Frame: 0-24hrs ]
- 0-24hrs PK of GW273225 Hormone levels with co-administration of oral contraceptive and GW273225 [ Time Frame: 0-24hrs ]
- blood drug levels of GW273225 in the presence or absence of the Combined Oral Contraceptive (COC) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dosing on Day 49 and Day 75 ]
- blood levels of ethinylestradiol and levonorgestrel of the COC in the presence or absence of GW273225. [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dosing on Day 21 and Day 49 ]
- blood levels of FSH, LH and progesterone [ Time Frame: Up to Day 45 ]
- blood levels of Oestradiol and SBHG [ Time Frame: Up to Day 45 ]
- Electrocardiogram (ECG) recordings [ Time Frame: Up to Day 96 ]
- Adverse events [ Time Frame: Up to Day 96 ]
- Vital signs [ Time Frame: Up to Day 96 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483535
|GSK Investigational Site|
|Cambridge, Cambridgeshire, United Kingdom, CB3 7TR|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|